Out Fox The $treet

NeoStem ( NBS ) is not only transforming the treatment of chronic disease, but the company is working to transform the stock as well. From the transition to the NASDAQ back in July to the hiring of new executives to help lead the next phase of development, NeoStem appears ready for the next growth stage. The company develops therapies for chronic unmet medical needs around a significant IP portfolio and operates a revenue generating service division with expertise in contract manufacturing and cell banking. With a market cap of only $150 million, the stock is largely unknown by the market, yet it has plenty of opportunities to address chronic diseases from cardiovascular disease to autoimmune disorders to regenerative opportunities. Read the full article at Seeking Alpha. Disclosure: No positions mentioned. Please review the disclaimer pages for more details. 

NeoStem ( NBS ) might be a small biotech stock, yet it has numerous irons in the fire that could provide huge growth opportunities. Cell therapy has the potential to radically change how diseases are treated, and the company plans to be a leader in the area. The company develops therapies for chronic unmet medical needs around a significant IP portfolio and operates a revenue generating service division with expertise in contract manufacturing and cell banking. NeoStem has several opportunities including a cardiovascular program, a very small embryonic like (VSEL) stem cell technology, a T cell program, and a contract development arm that all provide ample abilities for success individually. The key is developing a least one division into a money-generating machine to enrich shareholders. Read the full article at Seeking Alpha. Disclosure: No positions mentioned. Please review the disclaimer page for more details.